Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 9/20 | 0.54 |
| ▸ | GRM5 | P41594 | 8/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | PKLR | P30613 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | HTR6 | P50406 | 5/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2950170 | 0.86 | GRM5 (0.56) | MAOBGRM5PKMPKLRMAOA | |
| SCHEMBL29758920 | 0.78 | MAOB (0.64) | MAOBGRM5MAOANPC1ALDH1A1 | |
| SCHEMBL569174 | 0.78 | MAOB (0.64) | MAOBGRM5MAOANPC1ALDH1A1 | |
| SCHEMBL15818861 | 0.78 | MAOB (0.58) | MAOBGRM5MAOANPC1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL27916588 | 0.77 | MAOB (0.62) | MAOBGRM5MAOANPC1ALDH1A1 | |
| SCHEMBL3956732 | 0.76 | MAOB (0.56) | MAOBPKMPKLRHTR2CHTR2B | |
| SCHEMBL3093600 | 0.76 | HTR2C (0.56) | MAOBMAOAHTR2CHTR2BHTR6 | |
| SCHEMBL2953873 | 0.75 | HTR6 (0.50) | PKMPKLRHTR2CHTR2BHTR6 | |
| SCHEMBL27710430 | 0.75 | PKM (0.51) | PKMPKLRHTR2CHTR2BHTR6 | |
| SCHEMBL17141468 | 0.73 | MAOB (0.47) | MAOBGRM5PKMPKLRMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7759389-B2 | Chroman derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2010-07-20 | — | — | US | disclosed |
| US-7759389-B2 | Chroman derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2010-07-20 | — | — | US | disclosed |
| US-7759389-B2 | Chroman derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2010-07-20 | — | — | US | disclosed |
| US-7528250-B2 | Chroman derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2009-05-05 | — | — | US | disclosed |
| EP-1831191-B1 | CHROMAN DERIVATIVES AND THEIR USE AS 5-HT RECEPTOR LIGANDS | HOFFMANN LA ROCHE (CH) | 2008-05-21 | — | — | EP | disclosed |
| EP-1831191-B1 | CHROMAN DERIVATIVES AND THEIR USE AS 5-HT RECEPTOR LIGANDS | HOFFMANN LA ROCHE (CH) | 2008-05-21 | — | — | EP | disclosed |
| EP-1831191-A1 | CHROMAN DERIVATIVES AND THEIR USE AS 5-HT RECEPTOR LIGANDS | F. Hoffmann-Roche AG (CH) | 2007-09-12 | — | — | EP | disclosed |
| EP-1831203-A1 | CHROMAN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CNS DISORDERS | F. Hoffmann-Roche AG (CH) | 2007-09-12 | — | — | EP | disclosed |
| US-20060148820-A1 | Chroman derivatives and uses thereof | ROCHE PALO ALTO LLC | 2006-07-06 | — | — | US | disclosed |
| US-20060148888-A1 | Chroman derivatives and uses thereof | ROCHE PALO ALTO LLC | 2006-07-06 | — | — | US | disclosed |
| WO-2006066756-A1 | CHROMAN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-29 | — | — | WO | disclosed |
| WO-2006066746-A1 | CHROMAN DERIVATIVES AND THEIR USE AS 5-HT RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148820-A1 | Chroman derivatives and uses thereof | RB1, RECQL, CCNY | MAOB 773/4885GRM5 4202/4885PKM 778/4885 |
| US-20060148888-A1 | Chroman derivatives and uses thereof | RB1, RECQL, CCNY | MAOB 773/4885GRM5 4202/4885PKM 778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.